BOSTON SCIENTIFIC CORP
BSXNYSETrading Snapshot
- Day Range
- $50.50 – $51.54
- 52-Week Range
- $42.20 – $109.50
- Volume
- $7.46B
- Avg Volume
- $8.15B
- Shares Outstanding
- 1.49B
- Next Earnings
- Sep 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $20.89B
- Last Q Revenue
- $5.44B
- P/E Ratio
- 20.0
- P/S Ratio
- 3.5x
- EPS (TTM)
- $2.47
- Dividend Yield
- 0.00%
Why Investors Own BSX
- ✓High-growth profile — revenue up +6.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 71% gross margin and 15% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About BOSTON SCIENTIFIC CORP
A company profile for BOSTON SCIENTIFIC CORP isn’t available yet — check back soon.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Pulsed Field Ablation Global Market Report 2026 Now Available - Profiles Boston Scientific, Medtronic, Biosense Webster, and 15 Other Players
Pulsed Field Ablation Market Pulsed Field Ablation Market Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The "Pulsed Field Ablation Market by Therapeutic Area, Product Components, Application Area, Source of Ablation, Key Geographical Regions, and Sales Forecast of Leading Players - Trends and Forecast till 2035" has been added to ResearchAndMarkets.com's offering. The global pulsed field ablation market is projected to expand from approximately USD 3.2 billion in 2026 to USD 14.6 billion by 2035, re
Artisan Global Equity Fund Q2 2026 Portfolio Review
The portfolio underperformed the MSCI All Country World Index during Q2. Read more here.
Boston Scientific: The $5.4 Billion Quarter Tells Me The Sell-Off Is Overdone
Despite U.S. growth headwinds for WATCHMAN and electrophysiology, Boston Scientific delivered strong Q2 2026 results. Read why BSX stock is a Strong Buy.
Boston Scientific Stock Is Priced As If WATCHMAN Were The Whole Company
Two stalled franchises forced the guidance cut, and they sit outside the three quarters of revenue management still expects to grow at its long-run pace, with the shares now near the bottom of their decade on sales.
Boston Scientific Director Habiger Buys $100k of Shares Amid 54% Decline. What Does This Mean for BSX in 2026?
Habiger's $100,000 purchase expanded his direct holdings by 14%, signaling confidence despite the stock's recent weakness. The acquisition came as shares traded near their lowest levels in over a year.
Boston Scientific CEO Mahoney Buys More Than 200k Shares for $10 Million. What Does This Mean for Investors in 2026?
Mahoney expanded his equity stake by 13% following a -54% one-year stock decline. His combined holdings now total ~1.6 million shares valued at $78.08 million.